Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination With Rituximab in Subjects With Treatment Naïve Marginal Zone Lymphoma
Conditions
Interventions
Ibrutinib
Rituximab
+1 more
Locations
10
United States
George Washington Cancer Center
Washington D.C., District of Columbia, United States
Moffitt Cancer Center
Tampa, Florida, United States
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
Start Date
December 23, 2019
Primary Completion Date
March 18, 2027
Completion Date
March 18, 2027
Last Updated
July 23, 2025
NCT06149286
NCT05006716
NCT06026319
NCT07448324
NCT04195633
NCT06563596
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions